Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics
Autolus Therapeutics plc - American Depositary Share (AUTL)
Today's Latest Price: $13.44 USD
Updated Sep 21 6:55pm
Add AUTL to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
AUTL Stock Summary
- AUTL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.19 -- higher than merely 4.44% of US-listed equities with positive expected earnings growth.
- AUTL's price/sales ratio is 488.74; that's higher than the P/S ratio of 98.89% of US stocks.
- As for revenue growth, note that AUTL's revenue has grown -57.46% over the past 12 months; that beats the revenue growth of only 3.1% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Autolus Therapeutics plc are ASND, CRNX, FATE, QURE, and OTIC.
- Visit AUTL's SEC page to see the company's official filings. To visit the company's web site, go to www.autolus.com.
AUTL Stock Price Chart Technical Analysis Charts
AUTL Price/Volume Stats
| Current price | $13.44 | 52-week high | $17.19 |
| Prev. close | $14.28 | 52-week low | $3.00 |
| Day low | $13.17 | Volume | 119,000 |
| Day high | $14.22 | Avg. volume | 179,087 |
| 50-day MA | $14.66 | Dividend yield | N/A |
| 200-day MA | $11.80 | Market Cap | 604.57M |
Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio
Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.
Loading social stream, please wait...